疑似冠心病稳定门诊患者延迟检查:PRECISE随机临床试验预设二次分析
本研究为PRECISE试验的预设亚组分析,纳入2103例中422例(20%)经PROMISE最小风险评分(PMRS)判定为最小风险者,随机分为延迟检查组(n=214)与常规检查组(n=208)。
要点
- PMRS识别的最小风险患者延迟检查安全,主要终点事件显著少于常规检查。
- 延迟组64%未接受任何检查,36%后续检查中96%结果正常。
- 延迟组无创性梗阻性CAD导管术比例更低(0.9% vs 5.8%)。
核心结论
- 在疑似冠心病症状患者中,PMRS识别最小风险并初始延迟检查的策略安全,无观察到的死亡或心肌梗死,无梗阻性CAD导管术更少,症状缓解与常规检查相似。
研究设计与样本
- PRECISE随机实用有效性试验的预设亚组分析,在65个北美和欧洲中心进行。
- 纳入经PROMISE最小风险评分(PMRS)判定为最小风险的2103例参与者中的422例(20%)。
- 随机分为精准策略组(最小风险者延迟检查,n=214)或常规检查组(负荷试验或导管术,PMRS盲法,n=208),按PMRS风险分层随机。
主要发现
- 随访期间延迟组138例(64%)从未接受检查,76例(36%)后续检查中位时间48天(IQR 15-78),96%结果正常。
- 延迟组无死亡或心肌梗死,常规组有1例非心血管死亡和1例心肌梗死。
- 基线70%有频繁心绞痛,12个月时两组均降至不足20%,组间相似。
关键数值与推荐
- PROMISE最小风险评分(PMRS)用于识别最小风险患者。
- 主要终点为12个月内全因死亡、非致死性心肌梗死或无梗阻性CAD导管术的复合终点。
临床怎么用
- 对疑似冠心病稳定门诊患者,可用PMRS识别最小风险者并考虑初始延迟检查。
- 延迟检查策略可减少无梗阻性CAD的导管术,且不增加不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Guidelines recommend deferral of testing for symptomatic people with suspected coronary artery disease (CAD) and low pretest probability. To our knowledge, no randomized trial has prospectively evaluated such a strategy. OBJECTIVE: To assess process of care and health outcomes in people identified as minimal risk for CAD when testing is deferred. DESIGN, SETTING, AND PARTICIPANTS: This randomized, pragmatic effectiveness trial included prespecified subgroup analysis of the PRECISE trial at 65 North American and European sites. Participants identified as minimal risk by the validated PROMISE minimal risk score (PMRS) were included. INTERVENTION: Randomization to a precision strategy using the PMRS to assign those with minimal risk to deferred testing and others to coronary computed tomography angiography with selective computed tomography-derived fractional flow reserve, or to usual testing (stress testing or catheterization with PMRS masked). Randomization was stratified by PMRS risk. MAIN OUTCOME: Composite of all-cause death, nonfatal myocardial infarction (MI), or catheterization without obstructive CAD through 12 months. RESULTS: Among 2103 participants, 422 were identified as minimal risk (20%) and randomized to deferred testing (n = 214) or usual testing (n = 208). Mean age (SD) was 46 (8.6) years; 304 were women (72%). During follow-up, 138 of those randomized to deferred testing never had testing (64%), whereas 76 had a downstream test (36%) (at median [IQR] 48 [15-78] days) for worsening (30%), uncontrolled (10%), or new symptoms (6%), or changing clinician preference (19%) or participant preference (10%). Results were normal for 96% of these tests. The primary end point occurred in 2 deferred testing (0.9%) and 13 usual testing participants (6.3%) (hazard ratio, 0.15; 95% CI, 0.03-0.66; P = .01). No death or MI was observed in the deferred testing participants, while 1 noncardiovascular death and 1 MI occurred in the usual testing group. Two participants (0.9%) had catheterizations without obstructive CAD in the deferred testing group and 12 (5.8%) with usual testing (P = .02). At baseline, 70% of participants had frequent angina and there was similar reduction of frequent angina to less than 20% at 12 months in both groups. CONCLUSION AND RELEVANCE: In symptomatic participants with suspected CAD, identification of minimal risk by the PMRS guided a strategy of initially deferred testing. The strategy was safe with no observed adverse outcome events, fewer catheterizations without obstructive CAD, and similar symptom relief compared with usual testing. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03702244.
引用
- Udelson JE, Kelsey MD, Nanna MG, et al. Deferred Testing in Stable Outpatients With Suspected Coronary Artery Disease: A Prespecified Secondary Analysis of the PRECISE Randomized Clinical Trial. JAMA Cardiol. 2023. PMID: 37610768. doi:10.1001/jamacardio.2023.2614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。